Q-omics provides the consensus-scored GRIA4 profile across patient tissues and cancer cell-line models. GRIA4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GRIA4 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, GRIA4 RNA expression shows 15,271 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where GRIA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIA4 survival associations across molecular data types. GRIA4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIA4 RNA expression–survival associations across cancer types. High GRIA4 expression shows unfavorable associations in MESO, THCA and SCLC, but favorable associations in HNSC, KIRC and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GRIA4 RNA expression.
This table summarizes GRIA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GRIA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIA4 shows lower tumor expression in COAD, STAD, THCA, KICH and BRCA and higher tumor expression in KIRC. The COAD box plot shows higher GRIA4 RNA expression in normal versus tumor tissue (log2 FC = −0.453, t-test p < 0.001).
This table shows molecular features associated with GRIA4 in patient tissues and cancer cell lines. In patient samples, GRIA4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
